COMBINATION THERAPY WITH ANTI-CD74 AND ANTI-CD20 ANTIBODIES IN PATIENTS WITH RELAPSED AND REFRACTORY B-CELL NON-HODGKIN'S LYMPHOMA

摘要

The present invention concerns methods of treating relapsed/resistant non-Hodgkin's lymphoma using combination therapy with an anti-CD20 antibody or fragment and an anti-CD74 antibody or fragment. In preferred embodiments, the antibody combination is administered along with at least one other therapeutic agent. The combination is effective to treat indolent NHL that is resistant to or relapsed from at least one therapy for NHL, including but not limited to rituximab resistant NHL. The antibody combination may be administered to human subjects at specific dosages and dosing schedules, that are effective to treat the disease but do not induce a dose-limiting toxicity.

主权项

1. A method of treating non-Hodgkin's lymphoma, comprising administering to a human patient with non-Hodgkin's lymphoma (NHL) a combination of an anti-CD74 antibody or antigen-binding fragment thereof and an anti-CD20 antibody or antigen-binding fragment thereof, wherein the patient is relapsed from or resistant to at least one therapy for NHL.